Skip to Main Content
Skip Nav Destination

Locoregional Delivery of IL-13Rα2–CAR-T cells Is Safe in High-Grade Glioma

March 25, 2024

Major Finding: Locoregional administration of IL-13Rα2–CAR-T cells is feasible and well-tolerated in recurrent high-grade glioma.

Concept: Bioactivity and promising clinical benefit are observed with IL-13Rα2–CAR-T cell locoregional delivery.

Impact: These results suggest further efforts to enhance response and durability of these IL-13Rα2–CAR-T cells are warranted.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal